Clinical Study of Neurodegenerative Treatment on Glaucoma by Insulin Intravitreal Injection
Ophthalmology Research: An International Journal,
Purpose: Our trail was to study insulin intravitreal injection’s (IIV) efficacity and safety to treat glaucoma neurodegeneration.
Methods: Eleven subjects (11eyes) were recruited;10 patients treated in a double masked randomized sham controlled including 5 patients received one IIV injection 3UI and 5 patients received one injection of balanced salt solution(BSS) 3UI. A follow up during 168days was realized using Optical Coherence Tomography(OCT) and visual field(VF).The eleventh patient received two IIV injection without masking the injection content within one month between each injection and followed up for 877days.All the patients have a correct ocular pressure and no ocular treatment was stopped.
Results: The 5 patients who received IIV revealed a swift improvement of decibel (DB), and remains stable during the first month. The average improvement was 6.62DB during 168days.The 5 patients treated with one BSS injection showed no significant improvement regaining 1. 45DB.The last patient who received two injections showed increase from 7.54DB to 17.22DB with a functional amelioration of 9. 68DB.The OCT examination showed a structural improvement during the first month, then returned to the initial value. No complication was observed during and after the treatment.
Conclusion: Insulin shows not only efficacity and safety but more than that, the visual field(VF) of the patients became stable and show no deterioration in all the follow up, which confirmed that insulin act to improve the function rather than structure. it means insulin reconnect the stoma and improve the neurite outgrowth This treatment will change the evolution of this pathology and protect the glaucomatous patients against blindness.
- neurodegeneration disease
- neurite outgrowth
- visual field
- average defect
- nerve cells regeneration
How to Cite
Blumberg D, Skatt A, Liebmann JM. Chaopter 5 emerging risk factors for glaucoma onset and progression Prong Brain Res. 2015;221:81-101.
Noel CY, Chan MBCHB, FRCSED, Jane W, Chan MD. Glaucoma as a neurodegenerative disease: A clinician perspective. Advances in Ophthalmology and Optometry. 2021;263-274.
Paolini Paoletti F, Simoni S, Parnetti L, Gaetani L. The contribution of small vessel disease to neurodegeneration: Focus on Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. International Journal of Molecular Sciences. 2021;22(9):4958.
Agostinone J, Alarcon-Martinez L, Gamlin C, Wan-Qing Y, Wong OL, Di R, Polo A. Insulin signalling promotes dendrite and synapse regeneration and restores circuit function after axonal injury. 2018;141(7):1963-1980.
Johnston H, Boutin H, Allan SM. Assessing the contribution of inflammation in models of Alzheimer’s disease. Biochem Soc Trans. 2011; 39(4):886–90.
Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A. Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: Are microglia pathogenic in either disorder? .Int Rev Neurobiol. 2007;l82:235–46.
Pistell PJ, Morrison CD, Gupta S, Knight AG, Keller JN, Ingram DK et al. Cognitive impairment following high fat diet consumption is associated with brain inflammation. J Neuroimmunol 2010; 219(1–2):25–32.
Muneeb A. Faiq, Rima Dada, Daman Saluja, Tanuj Dada. Glaucoma – diabetes of the brain: A radical hypothesis about its nature and pathogenesis. Laboratory for Molecular Reproduction and Genetics, Department of Anatomy, All India Institute of Medical Sciences, New Delhi 110029, India c Medical Biotechnology Laboratory, Dr. B.R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi 110007, India; 2014. Available:http://dx.doi.org/10.1016/j.mehy.2014.02.005
Santos MS, Pereira EM, Carvaho AP. Stimulation of immunoreactive insulin release by glucose in rat brain synaptosomes. Neurochem Res. 1999;24(1):33–6.
Dupont, Le Roith. Clinical Endocrinology Branch, NIDDK, Bethesda, Md., USA. 2001;55(2):22– 26.
Leopold P. Neuronal differentiation: TOR and insulin receptor pathways set the tempo. Cell. 2004;119(1):4–5.
Weiss M, Steiner DF, Philipson LH. Insulin biosynthesis, secretion, structure, and structure-activity relationships. Endotext, K.R., Ed.; MDText.com, Inc.: South Dartmouth, MA, USA; 2000.
Havrankova J, Roth J, Brownstein MJ. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978;272:827–829.
Plum L, Schubert M, Brüning JC. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab. 2005;16:59–65.
Bateman JM, McNeill AH. Visions & reflections insulin/IGF signalling inneurogenesis. The wolfson centre for age- related disease, Hodgkin Building, King’s College London, Guy’s Campus, London, SE1 1UL (United Kingdom), Samuel Lunenfeld Research Institute, 600 University Avenue, Room 884, Toronto, Ontario M5G 1X5 (Canada).
Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/Mtor and Rac1 signaling pathways; Author links open overlay panelCheng-Che Lee Chiungè Chun Huang Kuei Sen Hsu. Neuropharmacolog. 2011;61(4):567-879.
Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci. 2003 ;23 (18):7084–92.
Xu QG, Li XQ, Kotecha SA, Cheng C, Sun HS, Zochodne DW. Insulin as an in vivo growth factor. Exp Neurol. 2004;188(1):43–51.
Evans RM, Hui S, Perkins A, Lahiri DK, Poirier J, Farlow MR. Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology. 2004;62(10):1869–71. DOI:10.1212/01.WNL.0000125323.15458.3F
Frodin M, Gammeltoft S. Role and regulation of 90 k Da ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol. 1999;151(1–2):65–77.
Abbott MA, Wells DG, Fallon JR. The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci. 1999;19(17):7300–8.
Yamaguchi A, Tamatani M, Matsuzaki H, Namikawa K, Kiyama H, Vitek MP, Mitsuda N, Tohyama M. Akt activation protects hippocampal neurons from apoptosis by inhibiting transcriptional activity of p53. J. Biol. Chem. 2001;276:5256–5264.
Dienstbier E, Balik J, Kafka H. A contribution to the theory of the vascular origin of glaucoma. Br. J. Ophthalmol. 1950;34:47–58.
Wareham KL, Calkins DJ. The neurovascular Unit in glaucomatous neurodegeneration. Front Cell Dev. Biol. 2020;8:452.
Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: Prevalence, pathogenesis and management. Nutr. Metab. Cardiovasc. Dis. 2010; 20:140–146.
Roddy GW. Metabolic syndrome is associated with ocular hypertension and glaucoma. J. Glaucoma. 2020;29:726–731.
Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev. Endocr. Metab. Disord. 2013;14:5–12
Kim AJ, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction Molecular and pathophysiological mechanisms. Circulation. 2006; 113:1888–1904.
Ryu BR, Ko HW, Jou I, Noh JS, Gwag BJ. Phosphatidylinositol 3-kinasemediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. J Neurobiol. 1999;39(4):536–46. DOI:10.1002/(SICI)1097-4695(19990615)39
Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol. Metab. 2010;21:589–598.
Devaskar SU, Giddings SJ, Rajakumar PA, Carnaghi LR, Menon RK, Zahm DS. Insulin gene expression and insulin synthesis in mammalian neuronal cells. J. Biol. Chem. 1994;269:8445–8454.
Schechter R, Beju D, Gaffney T, Schaefer F, Whetsell L. Preproinsulin I and II mRNAs and insulin electron microscopic immunoreaction are present within the rat fetal nervous system. Brain Res. 1996;736:16–27.
Das A, Pansky B, Budd GC, Kollarits CR. Immunocytochemistry of mouse and human retina with antisera to insulin and S- 100 protein. Curr. Eye Res. 1984;3:1397–1403.
Wei LT, Matsumoto H, Rhoads DE. Release of immunoreactive insulin from rat brain synaptosomes under depolarizing conditions. J Neurochem. 1990;54(5): 1661–5.
Kar S, Chabot JG, Quirion R. Quantitative autoradiographic localization of [125I] insulin- like growth factor I, [125I] insulin-like growth factor II, and [125I]insulin receptor binding sites in developing and adult rat brain. J Comp Neurol. 1993;333(3):375–97. DOI:10.1002/cne.903330306
Baura GD, Foster DM, Porte D Jr, Kahn SE, Bergman RN, Cobelli C et al. Saturable transport of insulin from plasma into the central nervous system of dogs In vivo. A mechanism for regulated insulin delivery to the brain. J Clin Invest. 1993;92(4):1824–30. DOI:10.1172/JCI116773
Rensink AA, Otte-Holler I, de Boer R, Bosch RR, ten Donkelaar HJ, de Waal RM et al. Insulin inhibits amyloid beta-induced cell death in cultured human brain pericytes. Neurobiol Aging 2004;25(1):93–103.
Reddy PH, Manczak M, Mao P, Calkins MJ, Reddy AP, Shirendeb U. Amyloid-b and mitochondria in aging and Alzheimer’sdisease: Implications for synaptic damage and cognitive decline. J Alzheimers Dis. 2010;20:499–512.
Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol. 1994;35(5):546–51.
Liu F, Shi J, Tanimukai H, Gu J, Grundke- Iqbal I, Iqbal K et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain. 2009;132(Pt 7):1820–32.
Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Brain glucose transporters, OGlc NAcylation and phosphorylation of tau in diabetes and Alzheimer’s disease. J Neurochem. 2009;111(1):242–9.
Aguirre V, Werner ED, Giraud J, Lee YH, Shoelson SE, White MF. Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem. 2002;277(2):1531–7.
Krebs DL, Hilton DJ. A new role for SOCS in insulin action. Suppressor of cytokine signaling. Sci STKE. 2003;2003(169):e6.
Tu YF, Tsai YS, Wang LW, Wu HC, Huang CC, Ho CJ. Overweight worsens apoptosis, neuroinflammation and blood-brain barrier damage after hypoxic ischemia in neonatal brain through JNK hyperactivation. J Neuroinflammation. 2011;8:40.
Al Awamlh S. AH, Lauren K. Wareham, Michael L. Risner, David J. Calkins. Insulin signaling as a therapeutic target in glaucomatous neurodegeneration. Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (M.L.R.) Department of Ophthalmology & Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Available:https://doi.org/ 10.3390/ijms22094672.
Abstract View: 132 times
PDF Download: 34 times